Immunotherapy and Tumor Microenvironment in HIV/AIDS Cancer Patients

HIV/艾滋病癌症患者的免疫治疗和肿瘤微环境

• 批准号: 10249752
• 负责人: ROBERT H VONDERHEIDE
• 金额: $ 7.34万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-12-01 至 2020-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10249752
• 关键词: AIDS/HIV problem; Address; Adoptive Immunotherapy; African; Basic Science; Behavior; Biology; Cancer Biology; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Patient; Catchment Area; Cause of Death; Clinical; Clinical Research; Clinical Sciences; Communities; Complex; County; Cutaneous; Delaware; Detection; Diagnosis; Education and Outreach; Environmental Impact; Fostering; Genetic; Genomics; Goals; Grant; Health; Immunotherapy; Informatics; Infusion procedures; Lead; Leadership; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of lung; Mesothelioma; Molecular; Molecular Epidemiology of Cancer; New Jersey; Obesity; Patients; Pediatric Hospitals; Pennsylvania; Philadelphia; Population Research; Population Sciences; Positioning Attribute; Prevention; Research; Resistance; Resources; Scientist; Skin tanning; Smoking; Statutes and Laws; Sun Exposure; Toxic Environmental Substances; Toxicology; Translations; United States; Universities; University Hospitals; behavior change; brain behavior; cancer care; cancer epidemiology; cancer therapy; cancer type; checkpoint therapy; clinical practice; cognitive neuroscience; environmental carcinogenesis; epigenomics; ethnic diversity; innovation; malignant breast neoplasm; melanoma; member; molecular imaging; novel; outreach program; patient oriented; personalized diagnostics; personalized medicine; precision oncology; prevent; programs; rare cancer; recruit; targeted treatment; therapy development; therapy resistant; tool; trait; tumor; tumor metabolism; tumor microenvironment; vaccine development

The goal of the Abramson Cancer Center (ACC) of the University of Pennsylvania is to bring together more than 310 members to transform the paradigm of patient-centered cancer care and cancer control by integrating high impact Programs of basic, clinical, and population-based research, fostering pioneering scientific discoveries, and facilitating the translation of these discoveries into clinical practice. In doing so, the ACC builds upon the great clinical cancer care at renowned hospitals of the University of Pennsylvania and the Children’s Hospital of the Philadelphia. The ACC continues to build on its significant historical strengths in basic cancer biology, translational immunotherapy, and population science research. By leveraging the infusion of new Institutional resources and significant philanthropic resources, the ACC will continue to innovate to reduce the burden of cancer in our catchment area during the next project period and will seek to: (1) Accelerate and expand its leadership in adoptive cellular immunotherapy, combination immune checkpoint therapies, and vaccine development for both prevention and treatment of cancers. (2) Increase translation of cancer basic biology through the philanthropic and Institutionally supported ACC Translational Centers of Excellence that integrate basic, translational and clinical scientists from the ACC Programs to impact on the prevention, detection, and treatment of specific types of cancers that afflict our catchment area. (3) Accelerate precision cancer medicine through novel Molecular Imaging, the Center for Personalized Diagnostics, the Molecular Tumor Board, and the Circulating Tumor Material Developing Core, which were implemented in the past project period, and the implementation of the Center for Rare Cancers and Personalized Therapy in the next project period. (4) Innovate means to understand, prevent, and treat therapy-resistant cancers by incorporating genomics, epigenomics, informatics and research in cancer metabolism, which is frequently re-wired in resistance to targeted therapies. (5) Lead population-based research through recruitment and research tools in genetics and complex traits with an emphasis on cancer epidemiology. Implement projects in cancer molecular epidemiology among patients of African descent and accelerate our Outreach Program to increase research relevant to our catchment area. (6) Launch a new Brain and Behavior Change initiative and harness new tools from cognitive neurosciences to control cancer by modulating behaviors that predispose to smoking or contribute to obesity. Lead in Toxicology and Environmental Carcinogenesis to understand environmental toxins and impact the health of patients with mesothelioma in our catchment area.

宾夕法尼亚大学艾布拉姆森癌症中心(ACC)的目标是汇聚更多 310多名成员通过整合以患者为中心的癌症护理和癌症控制的范式 基础、临床和基于人群的研究的高影响力计划，培养开创性科学 并促进将这些发现转化为临床实践。在这样做的过程中，接入 建立在宾夕法尼亚大学著名医院和 费城儿童医院。行政协调委员会继续在其重要的历史优势的基础上 基础癌症生物学、转化免疫疗法和人口科学研究。通过利用 注入新的机构资源和大量的慈善资源，行政协调会将继续 在下一个项目期间，创新以减轻我们集水区的癌症负担，并将寻求： (1)加速扩大在过继细胞免疫治疗、联合免疫领域的领先地位 检查点疗法，以及癌症预防和治疗疫苗的开发。 (2)通过慈善和制度支持的Access增加癌症基础生物学的翻译 翻译卓越中心，整合了来自Acc的基础、翻译和临床科学家 影响特定类型癌症的预防、检测和治疗的计划 集水区。 (3)通过个性化中心--新型分子成像加速精准癌症医学 诊断学、分子肿瘤委员会和循环肿瘤物质开发核心， 在过去的项目期内实施，以及罕见癌症和癌症中心的实施 个性化治疗在下一个项目期。 (4)通过整合基因组学创新了解、预防和治疗耐药癌症的手段， 表观基因组学、信息学和癌症新陈代谢研究，这经常被重新连接到对 有针对性的治疗。 (5)通过在遗传学和复杂性状方面的招募和研究工具，领导基于群体的研究 重点是癌症流行病学。实施癌症分子流行病学项目 非洲裔患者和加快我们的外联计划，以增加与我们的 集水区。 (6)启动新的大脑和行为改变倡议，并利用认知神经科学的新工具 通过调节易吸烟或导致肥胖的行为来控制癌症。入刀 毒理学和环境致癌认识环境毒素并影响健康 在我们集水区的间皮瘤患者中。